RESEARCH ARTICLE

FUT2 secretor genotype and susceptibility to infections and chronic conditions in the ALSPAC cohort [version 2; referees: 2 approved]

Meghan B. Azad¹, Kaitlin H. Wade², Nicholas J. Timpson ²

¹Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION), Children’s Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, R3E 3P4, Canada
²Medical Research Council Integrative Epidemiology Unit, Avon Longitudinal Study of Parents and Children, Population Health Science, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK

Abstract

**Background:** The FUT2 (fucosyltransferase-2) gene determines blood group secretor status. Being homozygous for the inactive “non-secretor” rs601338(A) allele confers resistance to certain infections (e.g. Norovirus, Rotavirus) and susceptibility to others (e.g. Haemophilus influenzae, Streptococcus pneumoniae). Non-secretors also have an increased risk of type 1 diabetes and inflammatory bowel disease. We examined FUT2 genotype, infections and chronic conditions in a population-based cohort.

**Methods:** We studied 7,582 pregnant women from the ALSPAC pregnancy cohort. Infections (measles, mumps, chicken pox, whooping cough, meningitis, herpes, gonorrhea and urinary infections) and chronic conditions (kidney disease, hypertension, diabetes, rheumatism, arthritis, psoriasis, hay fever, asthma, eczema and allergies) were self-reported. FUT2 secretor status was determined from the rs601338 genotype. ABO blood type was obtained from clinical records.

**Results:** Overall, 1920 women (25.3%) were homozygous for the non-secretor allele (AA). Secretor status was associated with mumps, with 68% of non-secretors experiencing this infection, compared to 48% of secretors (RR, 1.40; 95% CI, 1.34–1.46). A weaker association was observed for measles infection (76% vs. 72%; RR, 1.05; 95% CI, 1.02–1.09). Non-secretors also experienced an increased risk of kidney disease (5.4% vs. 3.9%; RR, 1.39; 95% CI, 1.11–1.75). Independent of secretor status, AB blood type was a risk factor for mumps (RR 1.15; 95%CI, 1.03, 1.28 compared to type O). We found no evidence of interaction between secretor status and blood type. For some conditions, including asthma and arthritis, FUT2 heterozygosity (GA) appeared to confer an intermediate phenotype. There was no strong evidence of association between secretor status and other infections or chronic conditions, although statistical power was limited for rare outcomes.

**Conclusion:** Our results identify an association between FUT2 secretor status and self-reported kidney disease, and confirm a recently reported association with susceptibility to mumps infection. The clinical implications of these associations warrant further investigation.

Open Peer Review

Referee Status:  

Invited Referees  

1  

2

Report

Report

version 2  

published 25 Sep 2018

version 1  

published 30 May 2018

Discuss this article

Comments (0)
Amendments from Version 1

We have revised our manuscript taking into account the reviewers’ suggestions. The main updates include: 1) incorporation of ABO blood group data; 2) expanded discussion of limitations related to self-reported data; 3) discussion of possible mechanisms for the observed association between FUT2 secretor status and kidney disease; 4) re-analysis accounting for two alternative null FUT2 alleles. These changes are detailed in our post-reviews to the reviewers’ comments.

See referee reports

Introduction

The FUT2 (fucosyltransferase 2) gene encodes the alpha (1,2) fucosyltransferase, which determines blood group secretor status. About 20% of Caucasians are homozygous for the nonsense mutation W143X (rs601338G>A), encoding a stop codon that inactivates the FUT2 enzyme. Individuals who are homozygous for this “non-secretor” allele (AA) are unable to secrete histo-blood group antigens into bodily fluids, or express them on mucosal surfaces.

Non-secretors have a lower risk of diarrheal illness and ear infections in childhood. The non-secretor phenotype also confers resistance to specific pathogens that require FUT2-dependent antigens to infect host cells, including Norovirus, Rotavirus, and Helicobacter pylori. By contrast, the non-secretor phenotype has been associated with increased susceptibility to other pathogens, including Candida, Neisseria meningitidis, and Streptococcus pneumoniae. Most recently, in a genome-wide association study (GWAS) of common infections, Tian et al. reported an increased susceptibility to mumps in non-secretors. In addition, non-secretors appear to be at increased risk for certain autoimmune diseases, including type 1 diabetes, psoriasis, and inflammatory bowel disease.

The above associations have not been simultaneously examined in a single population and several have not been independently replicated. Moreover, the association of FUT2 secretor status with other infectious and chronic diseases has not been widely studied. Finally, previous studies have typically only considered the secretor phenotype as dichotomous, assuming the non-secretor allele to be recessive. In this study, we characterized the association of FUT2 secretor status with a variety of infectious and chronic diseases in the population-based Avon Longitudinal Study of Parents and Children (ALSPAC), and examined the impact of heterozygosity for the non-secretor allele.

Methods

Study design and population

This study accessed data from the ALSPAC cohort. ALSPAC recruited 14,541 pregnant women (98% Caucasian) resident in the former county of Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992. The current analysis included a subset of 7,582 Caucasian women who selected and provided written informed consent for genotyping analysis, and reported their personal medical history during pregnancy. ABO blood group was collected from clinical records for the majority of participants (N=6,757). The ALSPAC website contains details of all the data that is available through a fully searchable data dictionary at http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.

Genotyping

ALSPAC mothers were genotyped using the Illumina human660W-quad array at Centre National de Génotypage (CNG) (Evry, France) and genotypes were called with Illumina GenomeStudio. PLINK (v1.07) was used to carry out quality control (QC) measures on an initial set of 10,015 participants and 557,124 directly genotyped single nucleotide polymorphisms (SNPs). SNPs were removed if they displayed more than 5% missingness or a Hardy-Weinberg equilibrium P value of less than 1.0x10^-6. Additionally, SNPs with a minor allele frequency of less than 1% were removed. Samples were excluded if they displayed more than 5% missingness, had indeterminate X chromosome heterozygosity or extreme autosomal heterozygosity. Samples showing evidence of population stratification were identified by multidimensional scaling of genome-wide identity by pairwise distances using the four HapMap populations as a reference, and then excluded. Cryptic relatedness was assessed using an identity by descent (IBD) estimate of more than 0.125, which is expected to correspond to roughly 12.5% alleles shared IBD or relatedness at the first cousin level. Related participants that passed all other QC thresholds were retained during subsequent phasing and imputation. In total, 9,048 mothers and 526,688 SNPs passed these QC filters.

Imputation

A total of 477,482 SNP genotypes in common between the sample of mothers described above and a second sample of 9,115 children were combined. SNPs with genotype missingness above 1% due to poor quality (N=11,396 SNPs) were removed and a further 321 participants were removed due to potential ID mismatches. This resulted in a dataset of 17,842 participants, containing 6,305 duos and 465,740 SNPs (112 were removed during liftover and 234 were out of HWE after combination). Haplotypes were estimated using ShapeIT (v2.r644), which utilizes relatedness during phasing. The phased haplotypes were then imputed to the Haploype Reference Consortium (HRC) panel of approximately 31,000 phased whole genomes using Impute V3. For this study, we excluded the mothers who had removed consent, leaving 8,698 eligible mothers. We further excluded those who did not provide personal medical history, leaving 7,582 for analysis.

Exposure: FUT2 genotype

FUT2 secretor status was defined based on the rs601338 SNP, where G is the wild-type “secretor” allele and A is the nonsense W143X “non-secretor” allele. Following previous studies, we considered the A allele to be recessive and dichotomized secretor status, combining the GA and GG genotypes as secretors and comparing them to the homozygous AA non-secretors. In addition, we explored the impact of GA heterozygosity at this locus. Two other commonly reported non-secretor alleles
were considered. The missense variant at rs1047781, described in Asian populations\textsuperscript{27} was not detected in our Caucasian population. The non-synonymous S258G variant at rs602662\textsuperscript{24} was highly correlated with rs601338; incorporating this SNP to define secretor status had no impact on 98% of participants’ phenotype classification, and did not materially change our results.

Outcomes: infections and chronic conditions
Infections and chronic conditions were self-reported using a standardized questionnaire during pregnancy. Women were asked if they had ever had various infections (measles, mumps, chicken pox, whooping cough, cold sores, meningitis, genital herpes, gonorrhea and urinary infections) or chronic conditions (diabetes, hypertension, kidney disease, rheumatism, arthritis, psoriasis, hay fever, asthma, eczema, and any allergies, including cat, dust, pollen, insect bites or ‘other’).

Statistical analysis
Demographic characteristics were summarized with descriptive statistics and compared between non-secretors (AA) and secretors (GA or GG combined) using t-tests for continuous variables or chi-squared tests for categorical variables. For each outcome, the relative risk (RR) and 95% confidence interval (95% CI) was calculated for non-secretors versus secretors. A multivariable model was used to determine whether the association of FUT2 secretor status and kidney disease was independent of measles, mumps and urinary tract infections. Multivariable models were also used to mutually adjust for FUT2 secretor status and ABO blood group and to formally test for interaction between these two factors. To explore the potential impact of FUT2 heterozygosity, a three group analysis was also conducted, considering the AA, GA and GG genotypes separately and using homozygous secretors (GG) as the reference group. All statistical analyses were performed in SAS (version 9.4, Carey, NC, US).

Results
Overall, 1920 women were homozygous for the FUT2 non-secretor allele (AA, 25.3%), 1906 were homozygous for the secretor allele (GG, 25.1%) and 3756 were heterozygous (GA, 49.5%). Almost half (46%) were first-time mothers, 21% were unmarried, 21% smoked, and 14% had a university degree. The mean (± standard deviation) age was 26.9 (± 5.9) years and the mean body mass index was 22.9 (± 3.7) kg/m\(^2\). These demographic characteristics were not associated with FUT2 secretor status (Table 1). The lifetime incidence of infections ranged from <1% for meningitis to 87% for chicken pox, while the incidence of chronic conditions ranged from 1% for diabetes to 43% for allergies.

Dichotomous FUT2 secretor status and infections
The homozygous AA non-secretor genotype was associated with mumps infection, with 68% of non-secretors experiencing this infection, compared to 48% of secretors (RR, 1.40; 95% CI, 1.34–1.46; p<0.0001) (Table 2). Weaker associations were observed for measles infection (76% vs. 72%; RR, 1.05; 95% CI, 1.02–1.09; p=0.0008) and urinary infections (57% vs. 55%; RR, 1.05; 95% CI, 1.00–1.10; p=0.05). There was no strong evidence of association between FUT2 secretor status and whooping cough, chicken pox or cold sores (Table 2).

Dichotomous FUT2 secretor status and chronic conditions
Homozygous AA non-secretors experienced a 39% increased risk of self-reported kidney disease compared to secretors (5.4% vs. 3.9%; RR, 1.39; 95% CI, 1.11–1.75; p=0.004) (Table 2). This association was essentially unchanged in a multivariable model controlling for mumps, measles and urinary infections (adjusted RR, 1.39; 95% CI, 1.10–1.75; p=0.005). Directionally consistent results were also observed for diabetes (RR, 1.23; 95% CI, 0.76–2.00; p=0.40), rheumatism (RR 1.19, 95%CI: 0.94–1.51, p=0.14) and arthritis (RR, 1.21; 95% CI, 0.93–1.57; p=0.15), although power was lacking for these relatively rare outcomes. There was no strong evidence of association between FUT2 secretor status and hypertension, hay fever, asthma or allergies (Table 2).

ABO blood group
Since secretor status determines the ability to secrete blood group antigens, we also explored the impact of ABO blood group on associations observed for mumps infection and kidney disease (Table 3). For both conditions, the effect estimate for FUT2 secretor status was essentially unchanged following adjustment for ABO blood group and there was no significant interaction.

Table 1. Demographics of mothers in the ALSPAC cohort according to FUT2 secretor status.

<table>
<thead>
<tr>
<th>FUT2 Secretor Status (rs601338 genotype)</th>
<th>Non-Secretors (AA)</th>
<th>Secretors (GG or GA)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=1920</td>
<td>N=5662</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>26.9 ± 5.9</td>
<td>26.9 ± 5.8</td>
<td>0.94</td>
</tr>
<tr>
<td>BMI, kg/m(^2)</td>
<td>22.8 ± 3.6</td>
<td>23.0 ± 3.7</td>
<td>0.05</td>
</tr>
<tr>
<td>Married</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>423 (22.4)</td>
<td>1173 (21.2)</td>
<td>0.28</td>
</tr>
<tr>
<td>Yes</td>
<td>1468 (77.6)</td>
<td>4364 (78.8)</td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td>0</td>
<td>861 (46.3)</td>
<td>2539 (46.2)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>641 (34.4)</td>
<td>1957 (35.6)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>264 (14.2)</td>
<td>738 (13.4)</td>
</tr>
<tr>
<td></td>
<td>3 or more</td>
<td>95 (5.1)</td>
<td>259 (4.7)</td>
</tr>
<tr>
<td>Smoking</td>
<td>No</td>
<td>1480 (78.8)</td>
<td>4324 (77.9)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>397 (21.2)</td>
<td>1229 (22.1)</td>
</tr>
<tr>
<td>Education</td>
<td>&lt;O level</td>
<td>457 (24.6)</td>
<td>1418 (25.8)</td>
</tr>
<tr>
<td></td>
<td>O level</td>
<td>642 (34.5)</td>
<td>1946 (35.4)</td>
</tr>
<tr>
<td></td>
<td>A level</td>
<td>461 (24.8)</td>
<td>1306 (23.8)</td>
</tr>
<tr>
<td></td>
<td>University degree</td>
<td>276 (14.8)</td>
<td>762 (13.9)</td>
</tr>
</tbody>
</table>

Values are mean ± standard deviation or n (%). AA, homozygous for non-secretor alleles; GG, homozygous for secretor alleles; GA, heterozygous; ALSPAC, Avon Longitudinal Study of Parents and Children; BMI, body mass index. Comparisons by t-test for continuous variables or chi-squared test for categorical variables.
Table 2. Lifetime incidence and relative risk of infectious and chronic conditions among mothers in the ALSPAC cohort according to dichotomized FUT2 secretor status.

<table>
<thead>
<tr>
<th>Condition*</th>
<th>FUT2 Secretor Status (rs601338 genotype)</th>
<th>Relative Risk Non-Secretors vs. Secretors</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-Secretors (AA)</td>
<td>Secretors (GA or GG)</td>
<td>RR (95% CI)</td>
</tr>
<tr>
<td></td>
<td>N=1920 cases (%)</td>
<td>N=5662 cases (%)</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>measles</td>
<td>1458 (75.9)</td>
<td>4076 (72.0)</td>
<td>1.05 (1.02, 1.09)</td>
</tr>
<tr>
<td>mumps</td>
<td>1299 (67.7)</td>
<td>2734 (48.3)</td>
<td>1.40 (1.34, 1.46)</td>
</tr>
<tr>
<td>chicken pox</td>
<td>1656 (86.3)</td>
<td>4925 (87.0)</td>
<td>0.99 (0.97, 1.01)</td>
</tr>
<tr>
<td>whooping cough</td>
<td>222 (11.6)</td>
<td>638 (11.3)</td>
<td>1.03 (0.89, 1.18)</td>
</tr>
<tr>
<td>cold sores</td>
<td>843 (43.9)</td>
<td>2458 (43.4)</td>
<td>1.01 (0.95, 1.07)</td>
</tr>
<tr>
<td>meningitis</td>
<td>15 (0.8)</td>
<td>61 (1.1)</td>
<td>0.73 (0.41, 1.27)</td>
</tr>
<tr>
<td>genital herpes</td>
<td>45 (2.3)</td>
<td>108 (1.9)</td>
<td>1.23 (0.87, 1.73)</td>
</tr>
<tr>
<td>gonorrhea</td>
<td>29 (1.5)</td>
<td>70 (1.2)</td>
<td>1.22 (0.80, 1.88)</td>
</tr>
<tr>
<td>urinary infection</td>
<td>1095 (57.0)</td>
<td>3085 (54.5)</td>
<td>1.05 (1.00, 1.10)</td>
</tr>
<tr>
<td>Chronic conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kidney disease</td>
<td>103 (5.4)</td>
<td>218 (3.9)</td>
<td>1.39 (1.11, 1.75)</td>
</tr>
<tr>
<td>hypertension</td>
<td>272 (14.2)</td>
<td>804 (14.2)</td>
<td>1.00 (0.88, 1.13)</td>
</tr>
<tr>
<td>diabetes</td>
<td>23 (1.2)</td>
<td>55 (1.0)</td>
<td>1.23 (0.76, 2.00)</td>
</tr>
<tr>
<td>rheumatism</td>
<td>93 (4.8)</td>
<td>230 (4.1)</td>
<td>1.19 (0.94, 1.51)</td>
</tr>
<tr>
<td>arthritis</td>
<td>77 (4.0)</td>
<td>188 (3.3)</td>
<td>1.21 (0.93, 1.57)</td>
</tr>
<tr>
<td>psoriasis</td>
<td>59 (3.1)</td>
<td>213 (3.8)</td>
<td>0.82 (0.62, 1.08)</td>
</tr>
<tr>
<td>hay fever</td>
<td>573 (29.8)</td>
<td>1742 (30.8)</td>
<td>0.97 (0.90, 1.05)</td>
</tr>
<tr>
<td>asthma</td>
<td>215 (11.2)</td>
<td>652 (11.5)</td>
<td>0.97 (0.84, 1.12)</td>
</tr>
<tr>
<td>eczema</td>
<td>469 (24.4)</td>
<td>1271 (22.4)</td>
<td>1.09 (0.99, 1.19)</td>
</tr>
<tr>
<td>any allergies</td>
<td>837 (43.6)</td>
<td>2412 (42.6)</td>
<td>1.02 (0.97, 1.09)</td>
</tr>
</tbody>
</table>

AA, homozygous for non-secretor alleles; GG, homozygous for secretor alleles; GA, heterozygous; ALSPAC, Avon Longitudinal Study of Parents and Children; RR, relative risk; CI, confidence interval.

*Self-reported during pregnancy: “Have you ever had…?”

Table 3. Mutually-adjusted associations of FUT2 secretor status and ABO blood group with mumps infection and kidney disease in the ALSPAC cohort

<table>
<thead>
<tr>
<th>FUT2 Genotype</th>
<th>Mumps</th>
<th>Kidney Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>% RR (95% CI)</td>
</tr>
<tr>
<td>Non-Secretor (AA)</td>
<td>1299/1920</td>
<td>67.7</td>
</tr>
<tr>
<td>Secretor (AG or GG)</td>
<td>2734/5662</td>
<td>48.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood Group</th>
<th>Mumps</th>
<th>Kidney Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1522/2917</td>
<td>52.2</td>
</tr>
<tr>
<td>B</td>
<td>316/608</td>
<td>52.0</td>
</tr>
<tr>
<td>O</td>
<td>1595/3015</td>
<td>52.9</td>
</tr>
<tr>
<td>AB</td>
<td>129/217</td>
<td>59.4</td>
</tr>
</tbody>
</table>

RR, relative risk; CI, confidence interval. Models are mutually adjusted for FUT2 genotype and blood group.
between *FUT2* and ABO blood group (p for interaction: 0.60 for mumps, 0.57 for kidney disease). Independent of *FUT2* secretor status, women with type AB blood had an increased risk of mumps infection (59.4%) compared to women with type A, B, or O blood (52.2%, 52.0%, 52.9%, respectively; adjusted RR 1.15, 95% CI: 1.03, 1.28 for AB vs O, p=0.01). ABO blood group was not associated with kidney disease.

**FUT2 heterozygosity**

Compared to homozygous GG secretors, GA heterozygotes experienced a similar risk of mumps infection (RR, 0.97; 95% CI, 0.91–1.02; p=0.24) and kidney disease (RR, 0.99; 95% CI, 0.75–1.30; p=0.93), suggesting that increased susceptibility to these conditions (as described above) is likely to be a recessive trait experienced only in homozygous AA non-secretors. Similar evidence was found for measles, urinary infections and eczema, where disease risk was comparable for individuals with GG and GA genotypes. However, this pattern was not consistent across all conditions. For example, the risk of asthma was similarly reduced in GA heterozygotes (11.1%) and AA non-secretors (11.2%) compared to GG secretors (12.2%), and the risk of arthritis was lower in GA heterozygotes (3.0%) compared to either homozygous genotype (4.0% in AA, 3.8% in GG), although statistical evidence of association was weak for these relatively rare outcomes (Figure 1).

**Discussion**

Our findings from the population-based ALSPAC cohort confirm and extend previous research associating the *FUT2* genotype with susceptibility to infections and chronic diseases. Specifically, we confirmed a recently reported association with mumps infection and identified an association with self-reported kidney disease. We also evaluated a number of other common conditions (e.g. whooping cough, chicken pox and asthma) but found no strong evidence of association with *FUT2* secretor status, indicating that *FUT2* influences pathogen- or disease-specific processes, rather than overall innate or adaptive immunity. Finally, our results suggest that *FUT2* heterozygosity may confer an intermediate phenotype for certain conditions, although further research is required to replicate these findings.

Our results confirm the association reported in a recent GWAS for common infections among 23andMe research participants by Tian et al., where the *FUT2* rs516316(C) allele was associated with mumps infection (odds ratio, 1.25; 95% CI, 1.24–1.27). This risk allele is in complete linkage disequilibrium with the non-secretor rs601338(A) allele evaluated in our study, where a strong association was also observed (RR, 1.40; 95% CI, 1.34–1.46). Tian et al. hypothesized that non-secretors are more susceptible to mumps infection because binding of the mumps virus to host cell sialic acid receptors is enhanced in the absence of sialic acid.
of FUT2-dependent antigens on the cell surface. Indeed, using x-ray crystallography and functional assays, Kubota et al. recently showed that mumps virus preferentially uses a trisaccharide containing α2,3-linked sialic acid in unbranched sugar chains as a receptor. Our results further evidence that susceptibility to mumps infection is modulated by FUT2 secretor status.

Tian et al. also reported an association between the ABO gene and mumps infection, and suggested that ABO antigens may disrupt binding of the mumps virus to host cell receptors. Our results using clinical ABO blood group data support and extend this finding by confirming an association and specifically identifying blood type AB as a risk factor for mumps infection. Since FUT2 secretor status determines whether ABO antigens are secreted into body fluids and onto cell surfaces, we hypothesized that secretor status and blood type may interact to influence susceptibility to mumps infection; however, we found no evidence of this interaction. Thus, our study suggests that FUT2 genotype and ABO blood group are independently associated with mumps infection, with increased risk among non-secretors and blood type AB.

Our study also provides new evidence that non-secretors may be predisposed to kidney disease (RR, 1.39; 95% CI, 1.11–1.75), although we lacked clinical information to confirm and classify this self-reported diagnosis. To our knowledge, the FUT2 genotype has not previously been associated with kidney disease in the general population, although some studies have used traditional blood group assays to evaluate secretor status in patients with pyelonephritis (kidney inflammation, typically due to bacterial infection). One study of women with acute uncomplicated pyelonephritis found that non-secretor status was significantly more common in these patients than in the general population, and another found that renal scarring in girls with recurrent pyelonephritis was more common in non-secretors than secretors. It has been hypothesized that these associations reflect an increased susceptibility to uropathogenic Escherichia coli infection among non-secretors, resulting from the enhanced expression of preferred binding receptors in the vaginal epithelium and kidneys of non-secretor women. Notably, in our study, the association between FUT2 genotype and self-reported kidney disease appeared to be independent of self-reported urinary infections. However, there are multiple clinically-distinct causes of “kidney disease” and “urinary infections”, and we lacked clinical information to define the etiology of these conditions in our study. Thus, additional research is needed to replicate our observations with confirmed and clinically-defined kidney disease and urinary infections, and to examine the possible relationship between these conditions and FUT2 genotype.

Consistent with previous studies, we observed a trend towards an increased risk of arthritis, rheumatism and diabetes among non-secretors, although we lacked statistical power for the analysis of these relatively uncommon autoimmune disorders.

Finally, we examined disease risk among GA heterozygotes, who are typically considered secretors because the non-secretor rs601338(A) allele is assumed to be recessive. Our results for mumps and kidney disease support this assumption, as increased susceptibility was only seen in homozygous AA non-secretors. However, we observed different patterns of association for some other conditions, including a potentially increased risk of gonorrhea and reduced risk of arthritis among GA heterozygotes, although our effect estimates were imprecise for these relatively rare conditions. Further research is warranted to replicate these observations in larger populations, and explore whether heterozygosity may impart an intermediate risk or unique protection from certain conditions.

Limitations of this work include the reliance on self-reported medical histories and low power for rare outcomes (such as meningitis, diabetes and other autoimmune diseases). Power was also limited for interaction analyses. Also, we could not identify the specific pathogens responsible for urinary infections, and we lacked clinical data to confirm, classify and define the etiology of multifactorial disorders (such as allergies and kidney disease). Finally, our analysis of the ALSPAC pregnancy cohort was limited to women, so the results may not be generalizable to men, and potential sex differences could not be investigated.

In conclusion, our results identify a novel association between FUT2 non-secretor status and increased risk of kidney disease, and confirm a recently-reported association with increased susceptibility to mumps infection. The clinical implications of these associations warrant further investigation.

Data availability
The ALSPAC data management plan (http://www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-plan.pdf) describes in detail the policy regarding data sharing, which is through a system of managed open access. The steps below highlight how to apply for access to the data included in this paper and all other ALSPAC data. The datasets used in this analysis are linked to ALSPAC project number B3047; please quote this project number during your application.

1. Please read the ALSPAC access policy (PDF, 627kB) which describes the process of accessing the data and samples in detail, and outlines the costs associated with doing so.

2. You may also find it useful to browse the fully searchable ALSPAC research proposals database, which lists all research projects that have been approved since April 2011.

3. Please submit your research proposal for consideration by the ALSPAC Executive Committee. You will receive a response within 10 working days to advise you whether your proposal has been approved.

If you have any questions about accessing data, please email alspac-data@bristol.ac.uk.

Grant information
This research was undertaken, in part, thanks to funding from the Canada Research Chairs program. The UK Medical Research...
Council and the Wellcome Trust (102215/2/13/2) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website. GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. MBA holds the Canada Research Chair in Developmental Origins of Chronic Disease. N.J.T. is a Wellcome Trust Investigator (202802/Z/16/Z), works within the University of Bristol NIHR Biomedical Research Centre (BRC) (IS-BRC-1215) and as part of the Cancer Research UK Integrative Cancer Epidemiology Programme (C18281/A19169). K.H.W. is fundedequally by two programs of the Medical Research Council Integrative Epidemiology Unit (MC_UU_12013/3 and MC_UU_12013/4). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This publication is the work of the authors and M.B.A. will serve as guarantor for the contents of this paper.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. We also thank Faisal Atakora (University of Manitoba) for assistance with data visualization, Laura Corbin (University of Bristol) for assistance with genotyping methodology, and Lars Bode (University of California San Diego) for assistance with interpretation of results.

References


Publisher Full Text


Open Peer Review

Current Referee Status: ✔️ ✔️

Version 2

Referee Report 27 September 2018
doi:10.21956/wellcomeopenres.16080.r33977

Jacques Le Pendu
CRCINA (Center for Research in Cancerology and Immunology Nantes-Angers), Inserm (French National Institute of Health and Medical Research), University of Angers, University of Nantes, Nantes, France

The authors have now adequately answered all of my queries.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 28 Sep 2018

Meghan Azad, University of Manitoba, Canada

Thank you Dr. Le Pendu for the helpful comments. We appreciate your input, and believe it has strengthened the paper.

Competing Interests: No competing interests were disclosed.

Referee Report 26 September 2018
doi:10.21956/wellcomeopenres.16080.r33978

Leonor David
Differentiation and Cancer Group, Institute of Molecular Pathology and Immunology of the University of Porto/Institute for Research and Innovation in Health of University of Porto (IPATIMUP/i3S), Porto, Portugal

The authors addressed my comments thoroughly and I hope that contributed to improve the paper.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Thank you, Dr. David. The paper is indeed improved thanks to your comments. We appreciate your input!

**Competing Interests:** None
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 14 Aug 2018

Meghan Azad, University of Manitoba, Canada

Thank you for your comments, Dr. David. Please see our point-by-point responses below in bold.

The paper entitled “FUT2 secretor genotype and susceptibility to infections and chronic conditions in the ALSPAC cohort”, identifies, in a cohort of 7,582 pregnant women, that the 25.3% homozygous for the FUT2 non-secretor allele have an increased incidence of mumps and a 39% increase in kidney disease. The association with mumps confirms a previous study by Tian et al, consolidates the implications of secretor status in this disease and increases the number of human infections linked to secretor status. We agree with Jacques Le Pendu on the interest to add the ABO status to enlarge the scope of the manuscript.

Please see our response to Dr. Le Pendu regarding ABO blood type. This has now been incorporated.

The association with kidney disease is a weaker point of the paper. The diseases were based on self-reporting and can therefore represent a wide range of entities with different etiopathogenesis. The association was however unchanged when controlling for urinary infections, again self-reported, despite that there was a weak association with urinary infection. If there is no possibility to access clinical data to clarify the etiopathogenesis of the kidney disease then a more careful approach should be used in writing these results.

We agree that it would be ideal to access clinical data to confirm and further classify these self-reported diagnoses. Unfortunately, clinical data are not available. We have
added “self-reported” ahead of “kidney disease” in the results and discussion, and we have expanded and reworded the discussion of these results and related limitations (please see above response to Dr. Pendu).

The associations between FUT2 heterozygosity and gonorrhea, where heterozygotes behaved similarly to non-secretors, is not significant and the relative risk in Figure 1 includes large confidence intervals (from <1 to 2).

We have removed the statement regarding gonorrhea.

Also, the authors should not conclude that there is absence of recessivity since they did not exclude the presence of other null/nonfunctional FUT2 alleles. This hypothesis could be tested by excluding alternative mutations, namely rs1047781 and rs602662.

Thank you for this suggestion. We have repeated our analysis accounting for these two alternative mutations, and the results are essentially unchanged. This is not surprising because:

- The rs1047781A>T mutation is only observed in Asian populations. As expected, it was not observed in our Caucasian population.
- The rs602662G>A mutation is highly correlated with the main rs601338 mutation that we have already analyzed. Accounting for this mutation identified an additional 155 non-secretors; the secretor status of the remaining 7427 individuals (98%) did not change.

We have now mentioned in the Methods section: “Two other commonly reported non-secretor alleles were considered. The missense variant at rs1047781, described in Asian populations (Ferrer et al. 2009) was not detected in our Caucasian population. The non-synonymous S258G variant at rs602662 (Barret et al. 2008) was highly correlated with rs601338; incorporating this SNP to define secretor status had no impact on 98% of participants’ phenotype classification, and did not materially change our results.”

In the analysis of population stratification the authors should explain why they used HapMap populations instead of 1000 Genomes, which includes more samples of the different human groups (European, Africans and Asians) and also have a deeper variation coverage.

HapMap was used because the analysis of population stratification was completed for the ALSPAC cohort before 1000 Genomes data were available. HapMap is adequate for checking overt ancestry as part of genotyping cleaning, especially because the ALSPAC cohort is 98% Caucasian, and genetic analyses were restricted to Caucasians (this information has now been added to the Methods). We have now cited the 2004 paper that describes this analysis (Pembrey et al. https://www.ncbi.nlm.nih.gov/pubmed/15554897). Note that for SNP imputation, which was completed more recently, we used the Haplotype Reference Consortium, which is even more fine-scale than 1000 Genomes.

**Competing Interests:** We have no competing interests to disclose.
The manuscript by Azad et al. describes the search for associations between the FUT2 genotype (or secretor phenotype) with several infectious diseases or chronic conditions from the ALSPAC cohort. Analysis of the rs601338 SNP from over 7500 women of the cohort revealed several significant associations, the two most striking ones linking the nonsecretor phenotype (AA genotype) to mumps and kidney disease. The relationship between the FUT2 AA genotype and mumps may be explained by the use of alpha2,3sialylated motifs as receptors for the MuV that would be hidden by the prior transfer of a fucose, as hypothesized earlier by Tian et al. This constitutes an important independent replication study for that particular association.

Specific comments:

- The Tian et al. study also described an association between mumps and the ABO genotype. Since the A and B blood group enzymes act in concert with the FUT2 enzyme, it would be interesting to analyse the ABO polymorphism in combination with the FUT2 genotype in order to get a better understanding of the genetics of susceptibility to mumps. This would be a significant improvement to the manuscript.

- A weakness of the study lies in the loosely defined clinical conditions that may limit the ability to uncover significant associations with the FUT2 status. Thus, a borderline association only was observed with non-defined urinary infection although a strong association between the nonsecretor phenotype and recurrent urinary tract infection caused by E. coli uropathogenic strains has been described several times. Likewise, the very interesting association observed between the FUT2 AA genotype and kidney disease leaves the reader unsatisfied since one would like to know the nature of the associated kidney diseases. Considering the above-mentioned infections by E. coli uropathogenic strains, an association with pyelonephritis would be expected. This limitations to the study should be discussed.

- From a methodological point of view, although I am not a statistician, I wonder if a correction for multiple testing would not be necessary since the authors tested for associations between the FUT2 status and 19 independent infectious or chronic conditions. This should be checked and the corrected analysis performed if required.

References

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 14 Aug 2018**

**Meghan Azad**, University of Manitoba, Canada

Thank you for your comments, Dr. Le Pendu. Please see our point-by-point responses below in bold.

The manuscript by Azad *et al.* describes the search for associations between the FUT2 genotype (or secretor phenotype) with several infectious diseases or chronic conditions from the ALSPAC cohort. Analysis of the rs601338 SNP from over 7500 women of the cohort revealed several significant associations, the two most striking ones linking the nonsecretor phenotype (AA genotype) to mumps and kidney disease. The relationship between the FUT2 AA genotype and mumps may be explained by the use of alpha2,3sialylated motifs as receptors for the MuV that would be hidden by the prior transfer of a fucose, as hypothesized earlier by Tian *et al.*. This constitutes an important independent replication study for that particular association.

**Thank you for these positive remarks.**

Specific comments:

- The Tian *et al.* study also described an association between mumps and the ABO genotype. Since the A and B blood group enzymes act in concert with the FUT2 enzyme, it would be interesting to analyse the ABO polymorphism in combination with the FUT2 genotype in order to get a better understanding of the genetics of susceptibility to mumps. This would be a significant improvement to the manuscript.

**Thank you for this suggestion.** We have now incorporated clinical blood group data in our analysis. This is described in the Methods, Results (new Table 3) and Discussion:

(METHODS) “ABO blood group was collected from clinical records for the majority of participants (N=6,757).” and “Multivariable models were also used to mutually adjust for FUT2 secretor status and ABO blood group and to formally test for interaction between
these two factors.”

(RESULTS) “Since secretor status determines the ability to secrete blood group antigens, we also explored the impact of ABO blood group on associations observed for mumps infection and kidney disease (SEE NEW TABLE 3: Mutually-adjusted associations of FUT2 secretor status and ABO blood group with mumps infection and kidney disease in the ALSPAC cohort). For both conditions, the effect estimate for FUT2 secretor status was essentially unchanged following adjustment for ABO blood group and there was no evidence of interaction between FUT2 and ABO blood group (p for interaction: 0.60 for mumps, 0.57 for kidney disease). Independent of FUT2 secretor status, women with type AB blood had an increased risk of mumps infection (59.4%) compared to women with type A, B, or O blood (52.2%, 52.0%, 52.9%, respectively; adjusted RR 1.15, 95% CI: 1.03, 1.28 for AB vs O, p=0.01). ABO blood group was not associated with kidney disease.”

(DISCUSSION) “Tian et al. also reported an association between the ABO gene and mumps infection, and suggested that ABO antigens may disrupt binding of the mumps virus to host cell receptors. Our results using clinical ABO blood group data support and extend this finding by confirming an association and specifically identifying blood type AB as a risk factor for mumps infection. Since FUT2 secretor status determines whether ABO antigens are secreted into body fluids and onto cell surfaces, we hypothesized that secretor status and blood type may interact to influence susceptibility to mumps infection; however, we found no evidence of this interaction. Thus, our study suggests that FUT2 genotype and ABO blood group are independently associated with mumps infection, with increased risk among non-secretors and blood type AB.” … “Power was limited for interaction analyses.”

- A weakness of the study lies in the loosely defined clinical conditions that may limit the ability to uncover significant associations with the FUT2 status. Thus, a borderline association only was observed with non-defined urinary infection although a strong association between the nonsecretor phenotype and recurrent urinary tract infection caused by E. coli uropathogenic strains has been described several times. Likewise, the very interesting association observed between the FUT2 AA genotype and kidney disease leaves the reader unsatisfied since one would like to know the nature of the associated kidney diseases. Considering the above-mentioned infections by E. coli uropathogenic strains, an association with pyelonephritis would be expected. This limitations to the study should be discussed.

We agree that the lack of precise clinical information is a limitation of our study. We have expanded our discussion of this limitation by adding the following sentence:

“We could not identify the specific pathogens responsible for urinary infections, and we lacked clinical data to confirm, classify and define the etiology of multifactorial disorders (such as allergies and kidney disease).”

We have also expanded our discussion of the results for kidney disease and urinary infections, citing evidence for uropathogenic E. coli and acute pyelonephritis. Thank you for this helpful suggestion. The revised paragraph now reads:

“Our study also provides new evidence that non-secretors may be predisposed to kidney disease (RR, 1.39; 95% CI, 1.11–1.75), although we lacked clinical information to confirm
and classify this self-reported diagnosis. To our knowledge, the FUT2 genotype has not previously been associated with kidney disease in the general population, although some studies have used traditional blood group assays to evaluate secretor status in patients with pyelonephritis (kidney inflammation, typically due to bacterial infection). One study of women with acute uncomplicated pyelonephritis found that non-secretor status was significantly higher in these patients than in the general population (Ishitoya et al. 2002), and another found that renal scarring in girls with recurrent pyelonephritis was more common in non-secretors than secretors. It has been hypothesized that these associations reflect an increased susceptibility to uropathogenic Escherichia coli infection among non-secretors, resulting from the enhanced expression of preferred binding receptors in the vaginal epithelium and kidneys of non-secretor women (Stapleton et al. 1992; Stapleton et al. 1998). Notably, in our study, the association between FUT2 genotype and self-reported kidney disease appeared to be independent of self-reported urinary infections. However, there are multiple clinically-distinct causes of “kidney disease” and “urinary infections”, and we lacked clinical information to define the etiology of these conditions in our study. Thus, additional research is needed to replicate our observations with confirmed and clinically-defined kidney disease and urinary infections, and to examine the possible relationship between these conditions and FUT2 genotype.”

- From a methodological point of view, although I am not a statistician, I wonder if a correction for multiple testing would not be necessary since the authors tested for associations between the FUT2 status and 19 independent infectious or chronic conditions. This should be checked and the corrected analysis performed if required.

Thank you for this suggestion. We considered correcting for multiple testing, but ultimately decided against this because the conditions may not be independent of each other (especially if similar or related FUT2-dependent mechanisms are influencing multiple conditions).

**Competing Interests:** We have no competing interests to disclose.